– 10 New Partnerships –
– Over 20 Milestones Achieved –
– 6 New Commercial Licenses –
Lebanon, NH – June 21, 2017 – Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that in the first half of 2017 it entered into agreements with six new companies. In addition, Adimab announced the expansion of four of its current partnerships and the achievement of over 20 technical and development milestones across multiple existing collaborations.
Over the past eight years, Adimab has entered into 50 partnerships for the discovery of therapeutic IgGs and bispecific antibodies, resulting in 175 therapeutic programs generated using the Adimab Platform. The most advanced program with partner Arsanis is currently in Phase II clinical trials. New alliances for 2017 include Anokion, Moderna Therapeutics, Mapp Biopharmaceutical, and Pionyr Immunotherapeutics, among others. In addition, Adimab expanded its collaborations with Celgene, Sanofi, and several others.
“Surface Oncology has been working with Adimab since its formation and we are about to start our seventh therapeutic program with them,” added Scott Chappel, Chief Technology Officer at Surface Oncology. “We know there are many options to discover antibodies but Adimab continues to perform beyond expectations. We are thrilled with our long-standing relationship with Adimab and they have made a big contribution to our success.”
“At Scholar Rock, we are committed to having the best possible therapeutic product candidates before investing millions of dollars in clinical development,” said Nagesh Mahanthappa, Chief Executive Officer and President of Scholar Rock. “Adimab was able to quickly generate antibodies that meet our desired selectivity requirements on complex targets, and we look forward to other future successes together.”
“We have focused on being the high-quality and not the low-cost provider – over the past eight years that has proven to be a very successful strategy,” commented Tillman Gerngross, Chief Executive Officer and Co-Founder of Adimab. “Many of our collaborators come to us with programs that have failed with other technologies and we get them back on track – when you commit to spending tens of millions of dollars on clinical trials you want to make sure that you are moving the best molecules forward. All our deals are structured that we win when our partners win – we are thrilled by their success.”
Adimab partners have exercised a total of six commercial licenses in the first half of 2017, including Biogen, Celgene, Checkpoint (a Fortress Biotech company), Potenza, and Surface Oncology.
Adimab has established partnerships with 50 pharmaceutical and biotechnology companies. The Adimab technology has been transferred and implemented at Merck, Novo Nordisk, Biogen and GSK. Funded discovery partners include leading pharmaceutical companies, such as Novo Nordisk, Biogen, GSK, Roche, Novartis, Eli Lilly, Genentech, Celgene, Gilead, Kyowa Hakko Kirin, Sanofi and others. Adimab has also partnered with many mid-size and early-stage venture-backed companies, including Merrimack, Five Prime, Jounce, Innovent, Alector, Acceleron, Surface Oncology, Potenza, Arsanis and others.
Adimab’s integrated antibody discovery and optimization platform provides unprecedented speed from antigen to purified, full-length human IgGs. Adimab offers fundamental advantages by delivering diverse panels of therapeutically relevant antibodies that meet the most aggressive standards for affinity, epitope coverage, species cross-reactivity and developability. Adimab enables its partners to rapidly expand their biologics pipelines through a broad spectrum of technology access arrangements. For more information, visit http://www.adimab.com.